PRESS RELEASE

MolMed signs a new multi-year agreement and announces the beginning of another collaboration in the field of rare diseases.

MolMed will perform development and GMP manufacturing services for a US based Nasdaq listed company.

Milan (Italy), March 18th 2020 – MolMed S.p.A. (MLMD.MI), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, announces the execution of a development and supply agreement with a leading, undisclosed, Nasdaq listed US based biopharmaceutical company, focused in developing cell & gene therapies for the treatment of rare diseases.

Under this agreement, MolMed will provide development and GMP manufacturing services for one or more of the client's preclinical and clinical programs across different rare disease indications.

Riccardo Palmisano, MolMed's CEO commented: "*This additional relevant agreement, signed just few days after the new collaboration we signed on March 6th, enlarges the basis of our portfolio in terms of both clients and projects, and confirms MolMed's strategy of consolidation of its leading position in the field of GMP cell & gene development and manufacturing. With this new agreement, we also confirm one of MolMed's key strength: the diversification in both viral vectors and cells, and in the fields of both oncology and rare diseases, offering a wide range of services based on the most required products and services in C&G field* ".

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed's is also developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. For more information please visit www.molmed.com.

For further information:

Molmed S.p.A.

Ilaria Candotti
Investor Relations & Communication Manager
MolMed S.p.A.
+39 02 21277.205
investor.relations@molmed.com

Tommasina Cazzato
Press Office
Community Group
+39 345 7357751
tommasina.cazzato@communitygroup.it